Reply To: Variants to mutations; fusions and

[Suzanne McGettigan]

Such a great question.
to add onto this conversation thread…

Not only have we seen many non-target mutations in known target-able genes such as BRAF, but also with some of the broader spectrum molecular panels available (either commercially or institution based) we are identifying a lot of mutations that we can’t necessarily target right now, outside of a clinical trial.